ADNI Phenotypes

Shannon L. Risacher
Indiana University School of Medicine

Friday Harbor Conference – September 6, 2017








Introduction

- ADNI provides numerous phenotypes to evaluate with genetic analysis, both with genome-wide and targeted analyses (i.e., pathway, gene-based)
- As a longitudinal study, many phenotypes are available both on a cross-sectional basis and a longitudinal basis
- The majority of phenotypes are available starting at the baseline visit, while some were only added at later timepoints

Introduction






Publication

2

Year

2008

Introduction



Common reported genes in manuscripts using ADNI genetic data (2008–2016)

Goals

- Describe ADNI visits and collection
- Describe ADNI clinical/cognitive phenotypes
- Describe ADNI fluid phenotypes
- Describe ADNI imaging phenotypes
- Briefly describe genomic analyses with ADNI phenotypes to date

ADNI Phenotypes

- ADNI is broadly divided into four phases
 - ADNI-1: Started enrolling in 2005
 - ADNI-GO: 200 early mild cognitive impairment (EMCI) patients enrolled starting in 2010
 - ADNI-2: Started enrolling in 2011
 - ADNI-3: Started enrolling in January 2017
 - "Roll over" of some participants through stages
- Participants include the following categories: cognitively normal (CN), significant memory concern (SMC; similar to SCD), EMCI, late MCI, and mild AD

ADNI Phenotypes

																											_												_			
								А	ADNI1									ADM	II GO: Ne	: New Participants		ADNI GO	Follow-U	o from ADN	1		ADNI2: New Participants										NI2: Follow-Up om ADNI1/GO	,				
Study Schedule	Scree	n	Base	line	м	lonth (6	Monti	h 12	Mont	th 18	Mon	th 24	Month 3	30 Month	36 Scre	een Ba	seline N	1onth 3	Month 6	Month 12	Month 18	Visit 1	Visit 2	Visit 3	Visit 4	Scree	n E	Basline	Month 3	Month	16	Month 12	Month 18	Month 24	Ongoing Month Int (phone	erim	Ongoing Annu	ual	Initial N	Ongoing 6	Ongoing Annual
																											CN EMCI/LMO	EMC	:N I/LMC	CN EMCI/LMC	CN EMCI/LM		CN MCI/LMC	CN EMCI/LMC	CN EMCI/LMC	CN		CN	EN	CN MCI/LMC	CN	CN EMCI/LMC
		AD (N M	CI AD	CN	MCI	AD I	CN MC	CI AD	CN M	CI AD	CN N	CI AD	CN M	CI CN N			MCI	EMCI	EMCI	EMCI	EMCI		CN/MCI	CN/MCI	CN/MCI		AD	I A	AD I	AD I	AD	ı AD	ı Al	D I A	D EMCI/LMCI	AD	MCI/LMCI A	AD		EMCI/LMCI	- 1
		Х	_	_			_	_	_		_		_										x				x	X									\vdash		-	x		
Domographics Family History	-	х	_	_	\vdash		_	_	-		_		_		+	,		_					×					×									\vdash		-	х		
Inclusion and Exclusion Criteria	×	x														>	٠										×	×									1 1			x		
Medical History, Physical Exam,		_	_	_			_	_	_		_	_	_			_	_	_					_		_		_		_		_	_					_		_			
Neurological Exam, Hachinski X	×	х								1 1		1 1				,	۱ '						×				×	×									1 1			×		
Vital Signs x	×	х	x x	×	х	x	х	х х	X	×		х	C X		х	x >	(x		х	х		×		x		x	x	x)	×	×	x	x		х			x		х		х
Height			\neg		П	\neg	\neg	_							$\overline{}$	-	·										×	х									П					
Screening Labs x	х	х)	(x	×														
	х	х	I									ш				\perp	\perp																									
DNA Sample Collection for APOE			Т															x					x		×				x >	×										x		
Genotyping and GWAS Cell Immortalization Sample			-	-													_																									
Collection Sample																		x				1		1	1		1		x >	×	1					1						
American National Adult Reading Test			x x	×														×											x >	x												
	x		-	_	-		-	x x	-	×		x			×	x >		-		x	×		×		×		×	-			×	×	x		х		\vdash	×	_	x		x
	×		_		^	^		x x			_	×			×			_			×		×		×			×			+-	-	X		^		х	×	_	×		×
Everyday Cognition (Ecog)	-		_	_	$\overline{}$	$\overline{}$	\rightarrow				_	-						×		×	×		X		×		-		x >	×	×	×	X		×		+ -	×	_	x		x
Montreal Cognitive Assessment			_				_	_					_			_	_	-										-				+	-						-			
(MoCA)																		x		×	×		×		×				x >	×	×	×	×		×		1 1	x		x		×
Digit Span	_		x x	x	х	х	х	х х	×	×		×	C X	-	х	×	\neg	-																			\Box					
Cateogory Fluency			x x	×	х	х	х	х х	х	×		х	< x		х	×																										
Category Fluency (Animals)	т	П			П		\neg					П			\top			×		×	х		×		×				x >	×	×	х	×		×		П	×		×		х
Trails A & B			x x		Х		х		Х	×			C X			×		х		х	х		х		х				x >	x	×	х	х		×			x		x		х
Digit Symbol								х х				х			х																											
Boston Naming Test								X X				х			х			x		х	х		×		x					x	×		х		х			x	_	x		х
Auditory Verbal Learning Test Geriatric Depression Scale x	-		x x	×	×	×		X X				X			×			х		×	×		×		×				x >	×	X		X		×		\vdash	×	_	×		x
Clock Drawing	×	х			-			x x				x			x		`	x		x	x		×		×		×	x	x >	×	x		x		x		\blacksquare	x	_	x		x
Neuropsychiatric Inventory	\vdash		^ _ ^	<u> </u>	<u> </u>	^	^	^ ^	+^	-	_		` ^	\vdash	1^	_	_	^	_	^			<u> </u>		<u> </u>		_			×	<u> </u>	-	X		×		\vdash	×	_	×		×
Neuropsychiatric Inventory Q	_		x x	×	×	×	×	хх	×	×		x	(X		×	×	_	х		×	×		×		×		+			^	×	×	^	×		×	х		_		x	
ADAS-Cog								x x				х			x																	-		-			1					
ADAS-Cog 13 (with Delayed																														-									-			
Word Recall and Number	1		- 1							l I				l I				×		×	x	1	×	1	×	l	1	1 1 :	x >	×	×	×	x		×	: [×		×		x
Cancellation)	L	ш		\perp	ш							Ш	\perp	Ш			\perp															ш					L.I					
Clinical Demetia Rating Scale x	X	Х						х х				х			х					х	х		х		×		x	x			x		х		х			x		x		х
Activities of Daily Living (FAQ)		\vdash	x x	×	×	×	х	x x	×	×	1	х	(X	\vdash	х	×	_	x		×	х		х		×		_	\vdash	× >	×	x	х	х		×		\vdash	x	_	x		х
Plasma and Serum Biomarker Collection																		x		×	x		×		×				x >	×	×	x	x		×			×		x		x
RNA Sample Collection		\vdash	-				-	-					-		+		-	x			×		×		×				x >				x		×		\blacksquare	X	-	x		×
Collect and Process Biomarkers		\vdash	x x	×	x	x	х	x x	×	×		x	(×		x	x		-					<u> </u>		<u> </u>				- 1	-			^^		1 1					^		^
	×	х										X			X			х		×	х	х	x	x	×	×	x	x	x >	×	x	х	х	×	: х	×		x	-	x	x	х
Subject Payments x		х										х			х																											
Phone Contact					П					х	х			x x																			х			x	х		_		х	
	Х	х												x x		x >	(x		x	х	х	х	х	х	×	х		X)	x	х	х	х		: x			х		x	х	х
Diagnostic Summary			x x	×	х	х	х	х х	х	х		х	C X		х	x		х		х	х		х		x		х	х	x >	x	х	х	х		х	: х		х		х		х
40.74 5 37.740007																																										
MRI (1.5 T) (100%) x MRI (3 T) (25%)	×	х						x x				X			X								Х		x				_										-			
MRI (3 T) (25%) MRI (3 T) (100%)		\vdash	^ ×	×	×	×	X	^ X	_ ×	×	-	^	\ X	\vdash	_ X	_			х		х	_					×	V .	-	x	x x	V	x	_	×		\vdash	x	-	x		х
PET (50%)			x .	Y	×	×	×	x x	×	×		x	C Y		×			-	^	^	^						_ ^			_ ^	^ ^	1	X		×			^	-	^		^
sF-AV-45 Amyloid Imaging		\vdash		+	1	_	^		Ť	H		Ĥ	1		+^+																								-			
(100%)																		x					×						x >	×					x			x		x		×
FDG-PET Imaging (100%)			1															х					х						x >	x					×			x	1	×		×
LP (minimum of 20%) CSF Collection by Lumbar			x x	×				x x	X						+		-	_																								
Puncture (100%)																		x					×						× >	x					×			×		×		х



ADNI General Phenotypes

	Д	DNI-	1	ADNI-GO	ADNI-1 roll over		P	ADNI-2	2		ADNI-1/GO roll over
	Screen/BL			Screen/BL	Visit 1	Visit 1 Screen/Baseline					
	CN	MCI	AD	EMCI	CN/MCI	CN	EMCI	LMCI	AD	SMC	CN/EMCI/LMCI
Approximate n	200	400	200	200	n/a	150	150	150	150	100	n/a
Explain Study	х	х	Х	Х	Х	Х	Х	Х	Х	Х	х
Obtain Consent	х	х	Х	х	х	Х	Х	Х	Х	Х	x
Demographics, Family History, Inclusion and Exclusion Criteria	x	x	x	X		x	x	x	x	x	
Medical History, Physical Exam, Neurological Exam, Hachinski	x	x	x	x	х	×	x	x	x	x	x

ADNI Clinical Phenotypes

	Д	ADNI-1			,	ADNI-GO)	ADNI-1/GO roll over	
	SC/BL	M6	Annual	Annual	SC/BL	M3	M6	Annual	Annual
	All	All	All	CN/MCI	All	All	All	All	CN/EMCI/LMCI
Height	х	X	х		х	x	x	х	
DNA Sample for APOE and GWAS	х	Х	х	х	х	Х	Х	х	х
Cell Immortalization Sample Collection					x	x	×	x	
Vital Signs (HR, BP, temp, weight)	Х	x	x	x	x	X	x	x	X
Medications	х	X	x	х	x	X	x	x	X
Adverse Events	х	Х	х	х	х	x	х	x	X
Diagnosis	х	Х	х	х	х	х	Х	х	X

ADNI Clinical/Cognitive Phenotypes

	P	ADNI-	-1	ADNI-1 roll over				ADNI	-GO/2				ADNI-1/GO roll over
	SC/BL	M6	Annual	Annual	SC/E	3L	МЗ	3	M6	3	Annı	ual	Annual
	All	All	All	CN/MCI	CN E/LMCI AD	SMC	CN E/LMCI AD	SMC	CN E/LMCI AD	SMC	CN E/LMCI AD	SMC	CN E/LMCI
American National Adult Reading Test	Х				Х	Х							
CDR	X	Х	X	X	Х	×			X	X	Х	X	X
FAQ	Х	Х	Х	Х	Х	Х			Х	Х	Х	Х	Х
GDS	Х	Х	Х	Х	Х	Х			Х	Х	Х	Х	Х
NPI/NPI-Q	Х	Х	Х	Х	Х	Х			Х	Х	Х	Х	Х
ADAS-Cog	Х	Х	Х	Х	Х	Х			Х	Х	Х	Х	Х
Neuropsych Battery	Х	Х	Х	Х	Х	Х			Х	Х	Х	Х	Х
MoCA				Х	Х	Х			Х	Х	Х	Х	Х
ECog (Self & Informant)				Х	Х	Х			Х	Х	Х	Х	Х
CCI-20 (Self)					X	Х							

ADNI Clinical/Cognitive Phenotypes

ADNI-1/GO/2 Battery

AMNART (Baseline only)

ADAS-Cog

MMSE

Weschler's Logical Memory I & II

Rey Auditory Verbal Learning Test

Clock Drawing

Trail Making A & B

Animal Fluency

Boston Naming Test

ADNI-1 only

Vegetable Fluency

Digit Symbol

Digit Span

ADNI-GO/2 only

MoCA

ECog

CCI-20 (SMC only)

ADNI Fluid Phenotypes

	,	ADNI-1			ADNI-1 roll over			ADNI-GO/2					
	SC/BL	M6	Annual	Visit 1	Annual	SC/BL	М3	M6	Annual	Annual			
	All	All	All	CN/MC	I CN/MCI	All	All	All	All	CN/EMCI/ LMCI			
Screening Labs	X					X							
Plasma and Serum Collection				Х	Х	Х		Х	Х	Х			
RNA Collection				Х	Х	Х			Х	Х			
					•								
	,	ADNI-	1		ADNI-1 oll over		ΑI	ONI-GO	D/2	ADNI-1/GO roll over			
	SC/BL	M6	Annual	Visit 1	Every 2 years	SC/BL	МЗ	М6	Every 2 years	Every 2 years			
	50%	50%	50%	CN/MCI	CN/MCI	All	All	All	All	CN/EMCI/ LMCI			
CSF Collection	Х	Х	X	X	X	X			Х	X			

ADNI Imaging Phenotypes

		ADNI-1			NI-1 over		ADN	II-GO/2	2		-1/GO over
	SC/BL	M6	Annual	Visit 1	Annual	SC/BL	М3	M6	Annual	Initial	Annual
	1.5T - All	1.5T - All	1.5T - All	1.5T - CN/MCI	1.5T - CN/MCI	All	All	All	All	CN	CN
	3T-25%	3T-25%	3T-25%	3T-25%	3T-25%					E/LMCI	E/LMCI
1.5T sMRI Scans	X	X	X	X	X						
3T sMRI Scans	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х
	ADNI-1				NI-1 over	ADNI-GO/2					-1/GO over
	SC/BL	M6	Annual	Visit 1	Every 2 years	SC/BL	М3	М6	Every 2 years	Every 2	2 years
	50%	50%	50%	CN/MCI	CN/MCI	All	All	All	All		N MCI
[¹⁸ F]FDG PET	Х	Х	Х	Х	Х	Х			Х	>	X
[¹¹ C]PiB PET	Selected	people, vari	ous visits								
[¹⁸ F]Florbetapir (AV-45) PET				Х	Х	Х			Х)	×
[¹⁸ F]Flortaucipir (AV-1451) PET						Selecte	ed peo	ple, va	rious visits	(earliest 2	24m FU)

ADNI Imaging Phenotypes

<u>ADNI-1 Sequence</u>

2 MPRAGEs – brain structure

PD/T2 – WM hyperintensities

<u>ADNI-1 Roll Over Sequence</u>

1 MPRAGE/SPGR

1 Accelerated MPRAGE/SPGR

2D FLAIR - WM hyperintensities

T2* - cerebral microbleeds

ADNI-GO/2 Sequence

1 MPRAGE/SPGR

1 Accelerated MPRAGE/SPGR

2D FLAIR

T2*

~1/3 of sample (each):

Diffusion Tensor Imaging (DTI) – WM integrity, structural connectivity

Arterial Spin Labeling (ASL) – brain perfusion

Resting-state fMRI – functional connectivity


RID: Unique Subject ID – most phenotypes coded by this ID


PTID: Full ID (Site ID _S_ Subject ID) – MRI and PET images and genetics are coded by this ID


VISCODE = Visit at which the data was collected


ADNI MERGE has many target variables but may not encompass all of the variables you are looking for...

Other Important Sheets: Neuropsychological battery (NEUROBAT), patient demographics (PTDEMOG), family history (FHQ, RECFHQ), CSF (UPENNBIOMK_MASTER), MRI (UCSFFSX51_08_01_16), Tau (UCBERKELEYAV1451), AV-45 (UCBERKELEYAV45), FDG (UCBERKELEYFDG), medications (RECCMEDS), medical history (MEDHIST), vital signs (VITALS), data dictionary (DATADIC), ADNI merge dictionary (ADNIMERG_DICT)











MR Imaging Phenotypes





SCHOOL OF **MEDICINE**

ADNI Imaging Phenotypes



Brain-Genome Association Strategies

Candidate Gene/SNP



Biological Pathway




Genome-wide **Analysis**


ROI




APC of Hippocampal Volume Diagnostic Group x ApoE r4 Genotype Risacher et al 2010




Circuit



Egan et al 2001 COMT




Swaminathan et al 2010 PiB **ROIs & amyloid pathway**




Potkin et al 2009 Mol Psych schizophrenia study


Whole **Brain**




Saykin, 2011



Reiman et al PNAS 2009; Also Ho et al 2010 FTO



Reiman et al 2008 cholesterol pathway genes




Shen et al 2010 ROIs; Stein et al 2010 voxels

ADNI Genetic Studies: Case/Control

Table 1 Association of ABCA7 variants with Alzheimer's disease in studied groups based on Fisher's association test, including age, gender, and PC as covariates. Gene-based analysis was conducted with CMC collapsing method

rsID/position ^a	MAF		OR	P
	Cases	Controls	(95 % CI)	
rs4147929	0.179	0.1581	1.162	0.022
(GWAS SNP)			(1.02-1.31)	
19:998507°	0.006	0.0037	1,735	0.121
p.Glu709AlafsX86			(0.54-3.04)	
19:1006907 ^a	0.003	0.0027	1.285	0.569
p.Leu1403ArgfsX7			(0.76-3.21)	
rs113809142	0.002	0.0012	1.695	0.451
c.4416+2T>G			(0.34-5.91)	
rs200538373	0.009	0.0076	1.231	0.476
c.5570+5G>C			(0.68-2.61)	
Loss-of-function	0.016	0.0107	1.549	0.038
(All low frequency variants)			(1.02-2.34)	


Single gene – ABCA7



Pathway/Network based (oxidative phosphorylation genes)




ADNI Genetic Studies: Case/Control



ADNI Genetic Studies: Clinical Status

FAQ values for e2 and non-e2 groups at


	ε2 M (SD)	non-ε2 M (SD)
Baseline	2.83 (6.4)	5.13 (6.6)
12 Months 1,2	3.53 (6.7)	6.90 (8.2)
24 Months 3, 4, 5	3.29 (6.8)	8.66 (9.5)



Single gene - APOE

Depressive Symptoms - GWAS

ADNI Genetic Studies: Cognition




Single	gene	- APOE
--------	------	--------

	Conservative PGRS (IGAP loci only)
Analyses within older participants without dementia (ADNI)	
Baseline memory	-0.069 (0.027); p = 0.01*
Longitudinal memory	-0.002 (0.007) p = 0.71
Baseline executive function	-0.029 (0.033); p = 0.37
Longitudinal executive function	0.005 (0.008); p = 0.53


AD risk genes - Pathway/Network based


ADNI Genetic Studies: Cognition



GWAS – episodic memory

ADNI Genetic Studies: CSF






Single gene – SORL1 (on CSF $A\beta_{1-42}$ level)

Pathway/Network based (immune pathway; Aβ/p-tau)




ADNI Genetic Studies: CSF








ADNI Genetic Studies: Blood



Higher plasma ApoE levels are associated with increased CSF A(I₁₋₄₂ concentrations in C-allele carriers (blue), but not in T-homozygotes (pink).





ADNI Genetic Studies: Blood





ADNI Genetic Studies: MRI







Single gene (APOE)


Pathway/Network based (Ventricle by Inositol-related genes)




ADNI Genetic Studies: MRI











rs9610775 (*CARD10*)






B. VBM

WES in extreme phenotype

ADNI Genetic Studies: Advanced MRI




Arteriolosclerosis gene (ABCC9) - ASL




APOE ε4 carriers – rsfMRI († connectivity of left hippocampus)

ADNI Genetic Studies: Advanced MRI




FA on DTI by CETP genotype

ADNI Genetic Studies: Amyloid PET




Single gene – APOE



Pathway/Network based (immune pathway; Aβ PET)

ADNI Genetic Studies: Amyloid PET




GWAS – longitudinal change in A β PET




ADNI Genetic Studies: FDG PET

APOE ε4 Effect



Single gene - APOE



AD risk genes - Pathway/Network based

ADNI Genetic Studies

For more information and a more comprehensive summary of papers see:

Saykin et al. (2015) Genetic Studies of Quantitative MCI and AD Phenotypes in ADNI: Progress, Opportunities, and Plans. *Alzheimer's & Dementia*, 11(7): 792–814.

Shen et al. (2014) Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers. *Brain Imaging & Behavior*, 8(2): 183-207.

Summary

- ADNI cross-sectional and longitudinal phenotypes provide an exceptional test-bed for many types of studies
- Numerous genetic studies in the ADNI dataset have been performed to date. However, a number of phenotypes, particularly those released most recently (advanced MRI, tau PET), have yet to be explored.
- More data will soon become available in ADNI-3.

Seeking Computational Neuroscience Post-Docs for Multi-Modality Imaging & Multi-omics Bioinformatics





